Seeking Alpha

Health Canada approves Medivation (MDVN) and Astellas' (ALPMY.PK) XTANDI (enzalutamide) for the...

Health Canada approves Medivation (MDVN) and Astellas' (ALPMY.PK) XTANDI (enzalutamide) for the treatment of metastatic castration-resistant prostate cancer. (Previous: XTANDI submitted to Japanese regulators; XTANDI sales rise)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|